2 results match your criteria: "and Hospital Clinico San Carlos Madrid[Affiliation]"
The Use of Botulinum Toxin in Strabismus Treatment.
J Binocul Vis Ocul Motil
December 2019
a Facultad de Medicina, IIORC, and Hospital Clinico San Carlos Madrid, Universidad Complutense de Madrid, Spain , Madrid , Spain.
There is a long and extensive experience with the use of Botulinum Toxin type A (BoNT-A) injection in the treatment of different types of strabismus and oculomotor palsies. The frequency of its use varies depending on the country and institution. It is a short procedure, may reduce general anesthesia exposure, causes minimal scarring compared to surgery, and can be proposed as an early treatment in unstable strabismus.
View Article and Find Full Text PDFα-Conotoxins Identify the α3β4* Subtype as the Predominant Nicotinic Acetylcholine Receptor Expressed in Human Adrenal Chromaffin Cells.
Mol Pharmacol
November 2015
Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain (A.J.H., A.A.); Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M., L.A.); George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah (J.M.M.); Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania (J.L.); Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona (L.L., P.W.); Hospital Doce de Octubre, Madrid, Spain (J.P.); and Hospital Clínico San Carlos Madrid, Spain (J.B.)
Ligands that selectively inhibit human α3β2 and α6β2 nicotinic acetylcholine receptor (nAChRs) and not the closely related α3β4 and α6β4 subtypes are lacking. Current α-conotoxins (α-Ctxs) that discriminate among these nAChR subtypes in rat fail to discriminate among the human receptor homologs. In this study, we describe the development of α-Ctx LvIA(N9R,V10A) that is 3000-fold more potent on oocyte-expressed human α3β2 than α3β4 and 165-fold more potent on human α6/α3β2β3 than α6/α3β4 nAChRs.
View Article and Find Full Text PDF